October 1, 1995Journal of Cardiovascular Electrophysiology
Proarrhythmia with Class III Antiarrhythmic Drugs: Definition, Electrophysiologic Mechanisms, Incidence, Predisposing Factors, and Clinical Implications
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Demands careful risk-benefit assessment with Class III agents; confirms proarrhythmic signals but leaves safer post-MI strategies unresolved.
Structured PICO
I
Intervention
Class III antiarrhythmic drugs (e.g., amiodarone, sotalol, d-sotalol)
Class III antiarrhythmic drugs carry a risk of proarrhythmia, specifically torsades de pointes, highlighting the need for careful risk-benefit assessment.
Cite This Study
Hohnloser et al. (1995) studied this question.